Lenvaxen 10 mg (Lenvatinib) Capsules

Lenvaxen 10 contains Lenvatinib 10 mg, a targeted anticancer medicine belonging to the multikinase inhibitor class. It works by blocking several receptor tyrosine kinases involved in tumor blood-vessel formation, cancer-cell signaling, and tumor growth.

Lenvatinib may be prescribed for specific types of advanced, unresectable, progressive, or metastatic cancers according to the patient's diagnosis and treatment plan.

Key Uses

• Differentiated Thyroid Cancer: Used for certain cases of radioactive iodine-refractory or progressive differentiated thyroid cancer.
• Renal Cell Carcinoma: Used in selected advanced kidney cancer treatment regimens, commonly in combination with another anticancer medicine.
• Hepatocellular Carcinoma: Used as a systemic treatment option for certain patients with unresectable liver cancer.
• Endometrial Cancer: May be used with pembrolizumab for certain advanced or recurrent endometrial cancers when appropriate treatment criteria are met.
• Targeted Cancer Therapy: Lenvatinib targets signaling pathways that cancer cells can use for growth and the development of new blood vessels.
• Tumor Growth Control: By inhibiting multiple kinase pathways, lenvatinib can help slow or control cancer progression in appropriate patients.
• Anti-Angiogenic Effect: It inhibits pathways involved in angiogenesis, the process through which tumors develop new blood vessels to support continued growth.

Active Ingredient

Lenvatinib 10 mg

Composition

Each Lenvaxen 10 capsule contains:

• Active Pharmaceutical Ingredient (API): Lenvatinib
• Strength: 10 mg
• Dosage Form: Capsule
• Therapeutic Category: Antineoplastic / Targeted Cancer Therapy
• Pharmacological Class: Multikinase Inhibitor

Lenvatinib is the pharmacologically active component responsible for the medicine's therapeutic activity. The capsule also contains inactive pharmaceutical excipients required for manufacturing, stability, capsule formation, and product performance.

How the Active Ingredient Works

Lenvatinib is a small-molecule tyrosine kinase inhibitor. It inhibits multiple receptor tyrosine kinases involved in angiogenesis and tumor growth. Important molecular targets include vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3) and other signaling receptors such as FGFR1–4, PDGFRα, RET, and KIT.

By interfering with these signaling pathways, lenvatinib can reduce signals responsible for the formation of new blood vessels around tumors and disrupt signaling involved in cancer-cell growth and survival.

Composition Summary:
Lenvatinib 10 mg per capsule

Patients should check the official product packaging or prescribing information for the complete list of inactive ingredients if they have known allergies or sensitivities to pharmaceutical excipients.

Lenvatinib dosing is individualized according to the type of cancer, treatment regimen, patient condition, organ function, tolerability, and other medicines being used. Therefore, Lenvaxen 10 should not be taken simply because the capsule contains 10 mg.

Standard Adult Dosing

The recommended dose varies according to the approved indication:

• Differentiated Thyroid Cancer: The usual recommended adult dose is 24 mg once daily.
• Renal Cell Carcinoma: When used with pembrolizumab, the usual recommended lenvatinib dose is 20 mg once daily. When used with everolimus, the usual recommended dose is 18 mg once daily.
• Hepatocellular Carcinoma: The recommended dose is based on body weight. Patients weighing 60 kg or more generally receive 12 mg once daily, while those weighing less than 60 kg generally receive 8 mg once daily.
• Endometrial Cancer: When used with pembrolizumab, the usual recommended lenvatinib dose is 20 mg once daily.

These are indication-specific recommended doses from prescribing information and must not be interpreted as a personal prescription. Dose modifications may be necessary because of adverse reactions, renal or hepatic impairment, or other clinical factors.

How to Take Lenvaxen 10

• Take the capsule exactly as prescribed by the oncologist.
• Lenvatinib is generally taken once daily at approximately the same time each day.
• It may generally be taken with or without food.
• Swallow the capsule whole with water.
• Do not crush, chew, or open the capsule unless a healthcare professional provides specific instructions.
• Take the medicine consistently according to the prescribed treatment schedule.
• Do not change the dose or treatment duration without consulting the prescribing physician.

Missed Dose

If a dose is missed, follow the instructions provided by the treating healthcare professional or the product's prescribing information. Do not take an extra dose to compensate for a missed dose.

If vomiting occurs after taking a dose, patients should generally not take an additional dose on the same day unless specifically instructed by their healthcare professional.

Dose Adjustment

Lenvatinib treatment may require temporary interruption, dose reduction, or discontinuation when significant adverse reactions occur. Dose adjustments may be considered for problems such as:

• Severe or persistent hypertension
• Significant proteinuria
• Renal impairment
• Hepatic toxicity
• Cardiac dysfunction
• Severe diarrhea
• Hemorrhage
• Other clinically significant adverse reactions

The treating oncologist should determine whether treatment should continue, be interrupted, reduced, or discontinued.

Important Administration Advice

Because lenvatinib can cause clinically important adverse reactions, patients receiving treatment may require regular monitoring of blood pressure, kidney function, liver function, urine protein, thyroid function, electrolytes, and other relevant clinical parameters.

Lenvatinib should only be used under appropriate medical supervision. Do not self-medicate, increase the dose, reduce the dose, or stop cancer treatment without speaking with the prescribing oncology team.